Tumor metastasis is the cause of death for 90% of cancer patients, and no 14 currently-available therapies target this multi-step process in which cancer cells 15 spread from the local tissue of a primary tumor to distant organs where they 16 establish secondary tumors 1 . Although epithelial-to-mesenchymal transition 2 , 17 tumor-secreted exosomes 3 , epigenetic regulators as well as other genes 4-8 have 18 been implicated in metastasis, little is known about how cells adapt to and 19 colonize new tissue environments. Here, we show that the epigenetics-mediated 20
and cell line studies that metastatic CRC cells lose their colon-specific gene 23 transcription program and gain a liver-specific gene transcription program as they 24 metastasize in the liver. Further, we found this transcription reprogramming is 25 driven by a reshaped epigenetic landscape of both typical and super-enhancers. 26
Chemical inhibition of enhancer activity disrupts the ability of cells to execute 27 altered transcription programs and consequently inhibits metastasis. Binding motif 28 analysis of the enhancers in liver metastatic CRC cells identified the liver-specific 29 transcription factor FOXA2 as a key regulator, and knocking down of FOXA2 30 expression prevents the colonization of metastatic CRC cells in the liver of a mice 31 xenograft model. These results, together with additional observations of similar 32 genes, which are regulated by general and cell-type-specific transcription factors 48 through regulatory genomic elements, such as enhancers, determines cell 49 identity 12-15 and may also promote macrophages adapting to a particular 50 environment in innate immune system 16 . 51
To explore the importance of tissue-specific genes during metastasis, we 52 4 initially evaluated the tissue-specific transcriptome profiles of primary and 53 liver-metastatic CRC tumors in three publicly available CRC datasets. Compared 54 with primary CRC tumors, liver metastatic CRC samples had up-regulated 55 expression of some commonly-known liver-specific genes and down-regulated 56 expression of commonly-known colon-specific genes (Fig. 1a, 1b ). To further 57 investigate these intriguing trends in gene transcription, we next performed an 58 unbiased Gene Set Enrichment Analysis (GSEA) 17 of these published datasets to 59 identify the statistically significant differences in global gene expression between 60 primary and liver-metastatic CRC tumors. We used the Genotype-Tissue 61 Expression (GTEx, https://gtexportal.org/home/) classification to define 62 tissue-specific gene signatures in this analysis. Consistent with our initial findings 63 for commonly-known liver and colon genes, the GSEA showed that the set of 64 significantly-upregulated genes in the liver-metastatic CRC tumors was 65 significantly enriched for a liver-specific signature (FDR < 0.00001), and the set of 66 genes with down-regulated transcription were significantly enriched for a 67 colon-specific gene signature (FDR < 0.00001) ( Fig. 1c, d, e ). We confirmed that 68 these enrichments were still significant even after removing up-regulated genes 69 that could possibly have been introduced by contamination from normal liver 70 tissues (Extended Data Fig. 1a, b, c) . Strikingly, additional analyses of primary 71 and metastatic tumors from other cancers using the same analysis and 72 5 classification criteria revealed that this apparent transcriptional reprogramming 73 also occurs in prostate-to-liver metastasis, prostate-to-bone metastasis, 74 kidney-to-lung metastasis and breast-to-lymph-nodes metastasis (Extended Data 75 Fig. 2a, b, c, d) . These findings suggest that metastatic cells can lose the 76 tissue-specific transcription program of the tissue from which they originate and 77 gain the tissue-specific transcription program of a distant tissue. Moreover, this 78 transcriptional reprogramming may be a common feature of metastasis in multiple 79 types of cancer. 80
Given the cellular heterogeneity of tumors, we sought to validate our initial 81 findings in experiments using pure CRC cell lines (Extended Data Fig. 3a) . 82 SW620 cells were originally derived from a lymph node metastasis and can easily 83 metastasize to liver in xenografts 18, 19 . SW480 cells were derived from primary 84 CRC tumor and show no ability to metastasize 18, 19 . SW620 and SW480 cells were 85 derived from the same patient 18 thus share the same genetic background, 86 providing an appropriate model to study reprogrammed transcription. RNA-seq 87 gene expression profiling revealed striking differences between non-metastatic 88 SW480 and liver-metastatic SW620 cells (Extended Data Fig. 3b ). GSEA of our 89 RNA-seq data for the two cell lines showed that a liver-specific gene signature 90 was enriched in the significantly up-regulated genes in SW620 cells (FDR = 0.02), 91 while a colon-specific gene signature was enriched in the significantly 92 6 down-regulated genes (FDR = 0.04) ( Fig. 1f ). Specifically, SW620 cells had 93 up-regulated expression of 112 liver-specific genes and down-regulated 94 expression of 77 colon-specific genes (Extended Data Fig. 3c, d) . Encouragingly, 95 about half of the up-regulated liver-specific genes and about one third of the 96 down-regulated colon-specific genes from the analysis of these two cell lines had 97 similar expression trends in primary and liver-metastatic CRC tumor samples ( Fig.  98 1g). Collectively, our results demonstrate that both liver metastatic CRC tumors 99 and CRC cell lines gain a liver-specific transcription program and lose a 100 colon-specific transcription program as these cells undergo metastasis. 101
Enhancers have been implicated in the regulation of tissue-specific or 102 cell-lineage gene expression 12 . We therefore used chromatin immunoprecipitation 103 sequencing (ChIP-seq) to investigate variations in the enhancer landscapes 104 between SW620 and SW480 cells. Analysis using two antibodies against 105 enhancer-specific histone modifications (H3K27ac and H3K4me2) showed that 106 the deposition patterns of H3K27ac and H3K4me2 differed significantly between 107 SW620 and SW480 cells ( Fig. 2a and Extended Data Fig. 4a, b ). An integrated 108 analysis of our RNA-seq and ChIP-seq datasets showed that genes with 109 up-regulated mRNA expression tended to be enriched in H3K27ac and H3K4me2 110 deposition near their genomic loci in SW620 cells ( Fig. 2b and Extended Data Fig.  111 4c). Analysis of liver-specific gene expression in SW620 cells also showed that 112 8 bromodomain containing 4 (BRD4) to enhancers 22 and thus inhibits enhancer 133 activity. We used JQ1 to disrupt the influence of enhancers on gene transcription 134 in SW620 cells to explore the role of reshaped enhancer landscapes in the 135 reprogramming of tissue-specific transcription in metastatic CRC cells. JQ1 136 treatment of SW620 cells resulted in the down-regulation of a set of liver-specific 137 genes ( Fig. 3a, b ). GSEA further confirmed the liver-specific gene signature was 138 significantly enriched in the set of down-regulated genes from JQ1-treated 139 SW620 cells (FDR = 0.005) ( Fig. 3c ). Further, we noted the SW620-unique 140 enhancers are more enriched near the genes that were down-regulated by JO1 141 treatment than common enhancers (P value = 4.148e-06, Fisher's exact test) ( Fig.  142 3d). Our JQ1 treatment results thus indicate that reprogramming of transcription 143 in metastatic CRC cells is driven by reshaped enhancer landscapes. BRD4 144 inhibitors have been reported to suppress CRC cells metastasizing to the liver in 145 mice, but very little is known about any related mechanisms of action 23 . Our 146 findings suggest that the anti-metastasis effect of BRD4 inhibition may be 147 conferred by preventing metastatic CRC cells from executing the liver-specific 148 transcription program that is specified and driven by an altered enhancer 149
landscape. 150
We conducted a de novo binding motif analysis that examined all of the 151 unique enhancers in SW620 cells (4,635) and found that the FOXA binding motif 152 9 was the most highly-enriched ( Fig. 4a and Extended Data Fig. 5a ). There are 153 three members of the FOXA gene family, and FOXA2 is a well-known liver 154 lineage-determining transcription factor 24 that was highly expressed in SW620 155 cells (Extended Data Fig. 5b ). ChIP-seq analysis with an antibody against FOXA2 156 showed that in SW620 cells FOXA2 occupied 35% of the SW620-unique 157 enhancers but only occupied 0.01% of the SW480-unique enhancers ( Fig. 4b and 158
Extended Data Fig. 5c ). Moreover, the deposition of H3K4me2 around FOXA2 159 binding sites was also significantly stronger in SW620 cells than in SW480 cells 160 (Extended Data Fig. 5d ). shRNA-based knocking-down of FOXA2 expression in 161 SW620 cells (Extended Data Fig. 6a ) resulted in significant down-regulation of 162 624 genes (> 50% decrease; FDR ≤ 0.05) (Fig. 4c ), and these genes were 163 generally located near FOXA2-bound enhancers (P value = 2.2e-16, by t-test) 164 (Extended Data Fig. 6b ). Considering the primary functions of the liver, we were 165 encouraged to find that a gene ontology analysis showed the top-ranked enriched 166 term among the down-regulated genes upon FOXA2 knocking down was 167 'metabolic process' (Extended Data Fig. 6c ). These results establish that FOXA2 168 binds to the SW620-unique enhancers in liver-metastatic CRC cells and 169 functionally activates a set of liver-specific genes. 170
We analyzed published gene expression datasets and found that FOXA2 171 was more highly expressed in human CRC liver metastases than in primary CRC 10 tumors ( Fig. 4d ). To exclude the possibility that contamination from normal liver 173 tissue may be responsible for the increased FOXA2 expression in the tumor 174 samples, we assessed FOXA2 protein levels by immunohistochemistry (IHC) in a 175 tissue microarray containing 18 liver metastases and 27 primary CRC tumors. 176
This result clearly showed that the FOXA2 protein levels are significantly higher in 177 liver metastatic CRC cells than in primary CRC cells (P value = 0.004, by t-test) 178 Supplementary Table 3 ). When we analyzed published clinical data, 179
we found that the subset of CRC patients with high expression levels for 180
FOXA2-targeted genes (91 genes, Supplementary Table 4 ) in their primary 181 tumors had significantly worse overall survival (P value = 0.006, by log-rank test) 182 and recurrence free survival (P value = 0.007, by log-rank test) outcomes than did 183 a subset of patients with low expression levels for these genes (Extended Data 184 shRNA had significantly fewer metastases that were also much smaller ( Fig. 4g-j) . We propose an 'original to distant transition' (ODT) working model to explain 205 our observations about the epigenetic reprogramming of tissue-specific 206 transcription that occurs in liver metastatic CRC cells ( Fig. 4k ). This model can 207 explain how the CRC cells from the colon can adapt to and colonize distant liver 208 tissue. Importantly, the ODT model predicts that there are multiple stages of the 209 reprogramming process that could be targeted therapeutically, including the 210 enzymes responsible for reshaping epigenetic landscapes and/or the transcription 211 factors or other regulators that function in the altered transcription programs. 212
This ODT process appears to occur in multiple cancer types, and similar 213 therapeutic strategies should in theory also work in other cancers. Recalling that 214 there are at present no therapies to treat metastasis, and considering that this 215 process causes the death of 90% of cancer patients, the mechanistic insights 216 from our study suggest a timely new conceptual framework for scientists and 217 clinicians to use as they seek to detect, treat, and perhaps even prevent 218 
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Proliferation assay 364
The effect of FOXA2 knockdown on SW620 cell proliferation was monitored in (RNA integrity number) >7 was used for RT-qPCR or RNA sequencing. 380
Tissues microarray and immunohistochemistry (IHC) 381
The human CRC tissue microarray (Shanghai Outdo Biotech Cat. No. 382
HLin-Ade075Met-01) containing 75 cases of normal colon tissues, primary CRC 383 19 tumors and metastases was purchased for IHC to determine FOXA2 expression. 384
Of the 75 cases, there were 27 primary tumors and 18 liver metastases. Matched 385 pairs of primary tumors and liver metastases are 18. IHC analysis was performed 386
by Outdo Biotech (Shanghai, China) using standard techniques as described 29 . 387
Briefly, all specimens on the tissue microarray were evaluated by H&E 388 (hematoxylin-eosin) staining to ensure the pathological types before IHC staining. 389
The tissue microarray was probed using the primary antibody (1:4,000 dilution) 390 against FOXA2 (Abcam Cat. No. ab108422). The degree of immunostaining was 391 scored by two independent investigators without prior knowledge of the clinical 392 data. The IHC scores were calculated as previously described 29 . In brief, more 393 than 1,000 tumor cells for each sample were analyzed under microscope. The 394 percentage of positively nuclear stained tumor cells was recorded and varied from 395 0%-100%. FOXA2 expression was quantified using a grading system based on 396 the percentage of FOXA2-positive cells, and the scores were as follows: 0, <5%; 397 1, 5%-24%; 2, 25%-49%; 3, 50%-75%; 4, >75%. The intensity of nuclear staining 398 was scored as follows: 0, no staining; 1, weak staining; 2, moderate staining; 3, 399 strong staining. A final IHC score was calculated as the product of the score of 400 "percentage of FOXA2-positive cells" and "intensity of staining". All primary data 401 are shown in Supplementary Table 3 . 402 20
Mouse model 403
Mice were housed in facilities managed by the Tsinghua University Animal 404
Resources Center and all experiments were performed in accordance with 405 Tsinghua University's Animal Care and Use Committee guidelines. SW620 cells 406 were under domestication in liver for three times. Briefly, we used 6-week-old 407 female Balb/c nude mice to domesticate SW620 cells. About 3 weeks later after 408 intrahepatic injection, the mice burdened with liver tumors were sacrificed. Liver 409 tumors were then resected and minced under sterile conditions. The minced 410 tissues were placed in DMEM medium with 100U/ml collagenase and 411 hyaluronidase for 1.5 hours at 37°C and then filtered by 200-mesh filter followed 412 by centrifugation. Next, cells were resuspended and grown in DMEM medium with 413 10% FBS. Intrahepatic injection was performed as described 26 
. Briefly, female 414
Balb/c nude mice, 5-8 weeks, were used for surgery. Mice were anesthetized with 415 avertin (From Tsinghua University Animal Resources Center). The skin was 416 incised and tumor cells (5x10 6 ) with shFOXA2 or shControl in 40 l PBS were 417 injected into the right liver lobe under the capsule. Mice were killed ~6 weeks later, 418 and the number of liver metastases and the metastatic area were quantified. 419
Subcutaneous injection of tumor cells was performed as described 26 . Briefly, 420 tumor cells (2x10 6 ) were resuspended in 40 l PBS and were injected 421 subcutaneously into the right flank of nude mice for 1 injection site per mouse. Six 422 21 days after injection and every 2 days thereafter, the length and width of tumors 423 were measured. Volume was calculated as length*width 2 /2 30 . 424
RNA-seq library preparation and sequencing 425
RNA-sequencing (RNA-seq) libraries were prepared by using the NEBNext Ultra 426
Directional RNA Library Prep Kit for Illumina (NEB Cat. No. E7420), according to 427 the manufacturer's instructions. The sequencing was performed by Hiseq1500 428 (Illumina). 429
RNA-seq and microarray data analysis 430
The fastq files from RNA-seq experiments were mapped to the human genome 431 (hg19) by using STAR 31 with parameters --outFilterMismatchNoverLmax 0.05. To 432 measure expression, we calculated the raw counts for each gene by using the 433 analyzeRepeats command from HOMER (http://homer.salk.edu/homer/) 32 with 434 the option "rna" and the default parameters. We identified genes with differential 435 expression between SW480 and SW620 cells by using edgeR 33 
ChIP-seq library preparation and sequencing 442
About 5-10×10 6 crosslinked cells were used for ChIP-seq, as described 41 . After 443 crosslinking, chromatin was fragmented by sonication, and the mixture was 444 All peaks between the different cell types per comparison were merged into 479 one peak set by using mergePeaks -size given. To obtain differentially bound 480 peaks, tags were counted from each experiment by using getDifferentialPeaks 481 24 and were considered significant with default parameters (4-fold difference and P 482 value = 0.0001). These enhancer regions with peak signals >4-fold in SW620 483 than in SW480 were named "SW620-unique" regions; the opposite regions were 484 named "SW480-unique" regions. The similarly bound peaks were determined by 485 using the same option. All peaks which were not part of either the differential 486 bound or similar bound peaks were filtered out. 487
Do novo motif finding and known motif enrichment 488
We used HOMER 32 with de novo motif discovery and known motif enrichment. 489
Motif finding for histone modification (H3K4me2, H3K27ac) regions distant from 3 490 kb up-and down-stream of TSS was performed on sequence from 1000 bp 491 relative to the peak center, whereas motif finding for transcript factors (FOXA2) 492 was performed on sequence of given length. Briefly, sequences were divided into 493 target and background sets. Background sequences were then selectively 494 weighted to equalize the distributions of G/C content in target and background 495 sequences to avoid comparing sequences of different general sequence content. 496
Motifs of 8, 10 and 12 bp were identified separately by first exhaustively screening 497 all oligonucleotides for enrichment in the target set compared with the background 498 set by using the cumulative hypergeometric distribution to score enrichment. Up 499 to two mismatches were allowed in each oligonucleotide sequence to increase the 500 sensitivity of the method. Top oligonucleotides for each length with the lowest P 501 25 values were then converted into probability matrices and heuristically optimized to 502 maximize hypergeometric enrichment of each motif in the given data set. As 503 optimized motifs were found, they were removed from the dataset to facilitate the 504 identification of additional motifs in subsequent rounds. HOMER also screens the 505 enrichment of known motifs previously identified by analysis of published 506
ChIP-ChIP and ChIP-Seq data sets by calculating the known motifs' 507 hypergeometric enrichment in the same set of G/C normalized sequences used 508 for de novo analysis. Sequence logos were generated using WebLOGO (http:// 509 weblogo.berkeley.edu). 510
Gene Set Enrichment Analysis 511
We defined tissue-specific gene sets by using the expression values yield by the 512 Genotype-Tissue Expression (GTEx) project. We downloaded the file that 513 contained the median RPKM of each gene by tissues and cell types from the 514 latest release version, V6p. For each gene, we ranked the median expression 515 value for each tissue or cell type in decreasing order. Genes defined as 516 tissue-specific needed to meet two criteria: 1) ranked in the top 5 among all tissue 517 and cell types and 2) also highly expressed (~90th percentile of all genes) in 518 particular tissues and cell types. The log2 ratios were computed for several 519 datasets from normalized expression data, including the primary versus liver 520 metastatic tumor samples from GSE41258 34 , GSE49355 35 ， GSE50760 40 , 521 26 GSE6919 36 , GSE32269 37 , GSE85258 38 and GSE59000 39 datasets, and the 522 DMSO versus JQ1 treatment on SW620 cells. Then, the pre-ranked Gene Set 523 Enrichment Analysis 17 was performed with tissue-associated gene sets and 524 dataset with default parameters. We show the scatter plot of FDR (q-values) 525 versus normalized enrichment score (NES) for each analysis. 526
Removing expression noises caused by contamination of host organ 527
In order to further confirm the tissue-specific gene signatures we found in the 528 patient samples, we removed differentially expressed probes/genes that could be 529
introduced by the contamination of distant organ (i.e. normal liver tissue) in the 530 metastasis samples. We adapted a published method 35 to remove ambiguous 531 probes/genes. Because hepatic metastasis (HM) sample may be contaminated by 532 certain normal hepatic tissue (HN), the measured expression value of HM for 533 each probe/gene, , is different from the real expression value: 534
where is the ratio of HN contamination in HM. Thus, we removed the 536 ambiguous up-regulated probes/genes between hepatic metastasis sample (HM) 537 and primary colon tumor (CT) using two criteria: where ̃ and ̃ are the median expression values of multiple samples in the 541 same data set. We assume the maximum contamination ratio is 20% ( = 0.2). 542
The results of different values of are shown in Extended Data Figure 8 as 543 well. For datasets (GSE49355, GSE50760) without normal liver tissue (HN), the 544 expression values of probes/genes in HN were calculated using corresponding 545 samples in GSE41258 (array) or GTEx database (RNA-seq). 546
We examined the enrichment of tissue-specific gene signatures with odds ratios 547 calculated from four numbers (Figure 1f , Extended Data Figure 8 ): (1) total 548 number of genes; (2) number of tissue-specific gene signatures (i.e. liver specific 549 genes defined by GTEx database); (3) number of up-regulated genes filtered by 550 the above two criteria; (4) number of liver specific genes filtered by the above two 551 criteria. P value of each odds ratio is calculated using Fisher's exact test. 552
We used the same strategy to examine the colon-sigmoid specific gene 553 signatures down-regulated in the metastasis samples (Extended Data Fig. 1) . 554
Kaplan-Meier survival analysis 555
We downloaded RNA-seq data for COAD patients with clinical data in the TCGA 556 from the NCI Cancer Genomics Hub (CGHub) 42 . For overall survival (OS) 557 analysis, the event call was derived from the "vital status" parameter. The 558 time_to_event is in days, equal to days_to_death if the patient died; if the patient 559 is still living, the time variable is the maximum (days_to_last_known_alive, 560 28 days_to_last_followup). For recurrence-free survival (RFS), the event call was 561 derived from the "new_tumor_event_after_initial_treatment" parameter. 
